-
公开(公告)号：US20230227441A1
公开(公告)日：2023-07-20
申请号：US18009306
申请日：2021-06-14
Applicant: Ashok ARASAPPAN , Ian M. BELL , Christopher James BUNGARD , Christopher S. BURGEY , Jason M. COX , Deodial Guy GUIADEEN , Michael J. KELLY , Mark E. LAYTON , Hong LIU , Jian LIU , James T. OLSEN , James J. PERKINS , Jeffrey W. SCHUBERT , Akshay A. SHAH , Michael D. VANHEYST , Zhe WU , Shawn J. STACHEL , MERCK SHARP & DOHME CORP.
Inventor： Ashok Arasappan , Ian M. Bell , Christopher James Bungard , Christopher S. Burgey , Jason Michael Cox , Deodial Guy Guiadeen, III , Michael J. Kelly, III , Mark E. Layton , Hong Liu , Jian Liu , James T. Olsen , James J. Perkins , Jeffrey W. Schubert , Akshay A. Shah , Shawn J. Stachel , Michael David VanHeyst , Zhe Wu
IPC: C07D413/12 , C07D263/24 , C07D417/12
CPC classification number: C07D413/12 , C07D263/24 , C07D417/12
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
-
公开(公告)号：US20220000844A1
公开(公告)日：2022-01-06
申请号：US17296601
申请日：2019-12-02
Applicant: Merck Sharp & Dohme Corp.
Inventor： Christopher J. Bungard , Helen Y. Chen , Jason M. Cox , Liangqin Guo , Michael J. Kelly, III , Ronald M. Kim , Mark E. Layton , Hong Liu , Jian Liu , Mehul F. Patel , James J. Perkins , Deping Wang , Walter Won , Younong Yu , Ting Zhang
IPC: A61K31/433 , C07D285/08 , C07D417/12 , C07D239/42 , A61K31/4439 , A61K31/505 , A61K31/5377 , A61K31/167
Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.
-
公开(公告)号：US10414775B2
公开(公告)日：2019-09-17
申请号：US16324604
申请日：2017-08-10
Applicant: Merck Sharp & Dohme Corp.
Inventor： John P. Caldwell , Mary Ann Caplen , Jared N. Cumming , Kevin D. Dykstra , Alan Hruza , Claire Lankin , Derun Li , Hong Liu , Amy McCracken , Brian McKittrick , Ashwin Rao , Jayaram Tagat , Haiqun Tang , Brandon M. Taoka , Andreas Verras , Shawn P. Walsh , Wen-Lian Wu , Tianyuan Zhang
IPC: C07D519/00 , C07D487/04 , C07D498/04
Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
-
4.发明申请公开(公告)号：US20190218223A1
公开(公告)日：2019-07-18
申请号：US16324596
申请日：2017-08-10
Applicant: Jared N. CUMMING , Kevin D. DYKSTRA , Alan HRUZA , Derun LI , Hong LIU , Haiqun TANG , Brandon M. TAOKA , Andreas VERRAS , Shawn P. WALSH , Wen-Lian WU , Merck Sharp & Dohme Corp.
Inventor： Jared N. Cumming , Kevin D. Dykstra , Alan Hruza , Derun Li , Hong Liu , Haiqun Tang , Brandon M. Taoka , Andreas Verras , Shawn P. Walsh , Wen-Lian Wu
IPC: C07D487/04 , C07D519/00 , C07D471/04 , C07D498/04 , C07D513/04 , A61P3/10
CPC classification number: C07D487/04 , A61P3/10 , C07D471/04 , C07D498/04 , C07D513/04 , C07D519/00
Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
-
5.发明申请SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 审中-公开替代苯唑嘌呤化合物及其用于治疗病毒性疾病的方法公开(公告)号：US20160130259A1
公开(公告)日：2016-05-12
申请号：US14898250
申请日：2014-06-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Hong Liu , Xing Dai , Anandan Palani , Shuwen He , Ravi Nargund , Dong Xiao , Qun Dang , Xuanjia Peng , Peng Li
IPC: C07D405/14 , C07D491/048 , C07D498/04 , C07D471/04 , C07D471/14 , A61K31/4985 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/497 , A61K31/506 , C07D413/14 , A61K45/06
CPC classification number: C07D405/14 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K45/06 , C07D405/04 , C07D413/14 , C07D471/04 , C07D471/14 , C07D487/14 , C07D491/048 , C07D498/04
Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Abstract translation: 本发明涉及可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5B聚合酶活性用于治疗或预防HCV感染的用途的式I化合物和 抑制基于细胞的系统中的HCV病毒复制和/或病毒生产。
-
Patent Agency Ranking
公开(公告)号：US11802122B2
公开(公告)日：2023-10-31
申请号：US17347639
申请日：2021-06-15
Applicant: Merck Sharp & Dohme Corp.
Inventor： Ashok Arasappan , Ian M. Bell , Christopher James Bungard , Christopher S. Burgey , Jason M. Cox , Michael J. Kelly, III , Mark E. Layton , Hong Liu , Jian Liu , James J. Perkins , Akshay A. Shah , Michael David VanHeyst , Zhe Wu
IPC: C07D403/12 , C07D233/32 , C07D401/12 , C07D401/14 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D513/04 , A61K31/4166 , A61P25/00 , A61P25/04 , A61P29/00
CPC classification number: C07D403/12 , C07D233/32 , C07D401/12 , C07D401/14 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D513/04
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
-
公开(公告)号：US20220024964A1
公开(公告)日：2022-01-27
申请号：US17299350
申请日：2019-12-02
Applicant: Merck Sharp & Dohme Corp.
Inventor： Michael D. Altman , Wonsuk Chang , Jared N. Cumming , Hong Liu , Benjamin Wesley Trotter
Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds (I).
-
公开(公告)号：US20210387966A1
公开(公告)日：2021-12-16
申请号：US17289123
申请日：2019-10-31
Applicant: Merck Sharp & Dohme Corp.
Inventor： Ashok Arasappan , Ian M. Bell , Michael J. Breslin , Christopher James Bungard , Christopher S. Burgey , Harry R. Chobanian , Jason M. Cox , Anthony T. Ginnetti , Deodial Guy Guiadeen , Kristen L. G. Jones , Mark E. Layton , Hong Liu , Jian Liu , James J. Perkins , Shawn J. Stachel , Linda M. Suen-Lai , Zhe Wu
IPC: C07D401/14 , C07D471/04 , C07D413/14 , C07D471/08 , C07D495/04 , C07D401/12 , C07D487/04 , C07D491/048
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
-
公开(公告)号：US20180237469A1
公开(公告)日：2018-08-23
申请号：US15886578
申请日：2018-02-01
Applicant: Merck Sharp & Dohme Corp.
Inventor： Michael D. Altman , Brian Andresen , Wonsuk Chang , Matthew Lloyd Childers , Jared N. Cumming , Andrew Marc Haidle , Timothy J. Henderson , James P. Jewell , Rui Liang , Jongwon Lim , Hong Liu , Min Lu , Alan B. Northrup , Ryan D. Otte , Tony Siu , Benjamin Wesley Trotter , Quang T. Truong , Shawn P. Walsh , Kake Zhao
IPC: C07H21/04 , C07H19/23 , C07H21/00 , C07H19/20 , A61K39/39 , C07H21/02 , A61K31/7076 , A61K31/708 , A61K31/706 , A61K31/7084 , A61K31/7064
Abstract: A class of polycyclic compounds of general formula (I), of general formula (I′), or of general formula (I″), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
-
公开(公告)号：US09809568B2
公开(公告)日：2017-11-07
申请号：US15035255
申请日：2014-11-10
Applicant: Merck Sharp & Dohme Corp.
Inventor： Duane DeMong , Michael Miller , Hong Liu , Xing Dai , Thomas Greshock , Andrew Stamford , Ravi Nargund
IPC: C07D401/04 , C07D401/14 , C07D231/56
CPC classification number: C07D401/04 , C07D231/56 , C07D401/14
Abstract: The present invention is directed to substituted indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
-
-
-
-
-
-
-
-
-
Search Results
37
records
(took 0.029 seconds)
